Myogenes Clozapine Test promises to improve outcomes for schizophrenia patients

FHS
October 4, 2024
11:34 am

Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.

Taylor Swift’s Ode to Medicine? Luxury Scrubs Gone Too Far; RN vs MD Salaries

The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. Is Taylor Swift’s new album, “The Tortured Poets Department,” an

April 26, 2024

Madrigal says it’s ‘well on the way’ to potential NASH launch ahead of FDA decision: #JPM24

SAN FRANCISCO — Madrigal Pharmaceuticals will be “ready to go” if the FDA grants its nonalcoholic steatohepatitis hopeful an accelerated approval in March, the company’s

January 12, 2024

Sugary drinks linked to higher dementia risk, new study from UK Biobank reveals

The study finds that consuming free sugars, especially through beverages like fruit drinks, sodas, and milk-based drinks, is associated with an increased risk of dementia,

November 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.